News and Comments

Biogen Idec Pays Elan $3.25 billion For Tysabri. Do We Leave, Or Stay?

  Wednesday, February 06, 2013

 More...

Elan's Choices

  Saturday, April 16, 2011

Biogen Idec (BIIB) announced positive results of a process aimed at Identifying high-risk patients for a life-threatening side effect of prolonged use of the multiple sclerosis drug Tysabri. This test is a necessity because it detects an antibody that points to the presence of the Polyomavirus JC (JC virus), which causes the life-threatening progressive multifocal leukoencephalopathy (PML). This side effect in one per thousand patients has deprived Elan from billions of dollars in expected sales of Tysabri.  More...


Recent Postings


Archive


Tags

Amgen (AMGN) Anacor (ANAC) CompuGen (CGEN) Micromet (MITI) Sanofi-Aventis (SAN) Ridaforolimus Genentech Intrexon (XON) Galena (GALE) JUNO (JUNO) Ziofpharm (ZIOP) Dendreon (DNDN) ZALTRAP™ Dynavax (DVAX) Biogen Idec (BIIB) Valeant Pharmaceuticals International (VRX) Regeneron (REGN) Zerenex Incyte (INCY) Exelixis (EXEL) Auspex (ASPX) NANTKWEST (NK) Human Genome Sciences (HGSI) Multiple Myeloma Roche (RHHBY) galapagos (GLPG) ABBVIE (ABBV) Pluristem (PSTI) Biocryst (BCRX) NEKTAR (NKTR)) ADVENTRIX (ANX) Vertex (VRTX) Onyx (ONXX) Mirati Therapeutics (MRTX) Sanofi (SNY) SUNESIS PHARMACEUTICALS (SNSS) Agenus (AGEN Prolor Biotech (PBTH) Alnylam (ALNY) Rapamune Velcade (bortezomib) ImmunoGen (IMGN) Sequenom (SQNM) Bristol-Myers Squibb (BMY) GlaxoSmithKline (GSK) Abbott Laboratories (ABT) Sangamo (SGMO) Sarepta (SRPT) Aimmune Therapeutics (AIMT) Inovio (INO) KITE (KITE) Idenix (IDIX) Roche (ROCHE) Seattle Genetics (SGEN) Trastuzumab-DM1 Intermune (ITMN) Ariad (ARIA) Intercept (ICPT) Prosensa (RNA) Revlimid (lenolidamide) SERES THERAPEUTICS (MCRB) Cytokinetics (CYTK) Theravance (THRX) Sanofi (SNA) Gilead (GILD) OSI (OSIP) Xoma (XOMA) Elan (ELN) Agenus (AGEN) BIOMARIN (BMRN) Jazz Pharmaceuticals (JAZZ) ISIS (ISIS) Illumina (ILMN) GUARDIAN HEALTH ARCA (ABIO) AERIE PHARMACEUTICALS HALOZYME (HALO) IDERA (IDRA) Array Pharmaceuticals (ARRY) Endometrial Cancer SYNTA (SNTA) Anadys (ANDS) VANDA (VNDA) KERYX (KERX) TOKAI (TKAOI) Telaprevir Tysabri C4 Therapeutics Benlysta (belimumab) Herceptin Merck (MRK)